CABOMETYX® (Cabozantinib)

The FDA on January 14, 2019 approved CABOMETYX® for patients with HepatoCellular Carcinoma (HCC) who have been previously treated with NEXAVAR® (Sorafenib). CABOMETYX® is a product of Exelixis, Inc.